Melanotan I

FDA Approved

Melanotan I (Afamelanotide)

Aliases
Afamelanotide, Scenesse
Administration
Subcutaneous implant (FDA-approved route)

Documented side effects

Tier 1 · Peer-reviewed / regulatory

Nausea

A common digestive side effect, often most noticeable when starting or increasing the dose.

Implant site reactions

Mild irritation or discomfort can occur at the site where the implant is placed.

Headache

A commonly reported mild side effect.

Skin darkening

A direct result of this compound's melanin-stimulating activity.